Impact Factor 4.259 | CiteScore 4.30
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Microbiol. | doi: 10.3389/fmicb.2019.02325

The therapeutic effect of 1,8-Cineol on pathogenic bacteria species present in chronic rhinosinusitis

 Matthias Schürmann1,  Felix Oppel1, Martin Gottschalk2, Björn Büker3,  Christian A. Jantos4,  Cornelius Prof. Dr. Knabbe5, Andreas Hütten2,  Barbara Kaltschmidt6, Christian Kaltschmidt7 and  Holger Sudhoff1*
  • 1Bielefeld Clinic, Germany
  • 2Faculty of Physics, University of Bielefeld, Germany
  • 3Bielefeld University, Germany
  • 4Institute of Laboratory Medicine, Microbiology and Hygiene, Evangelical Hospital Bethel, Germany
  • 5Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Germany
  • 6Molecular Neurobiology, Faculty of Biology, University of Bielefeld, Germany
  • 7Department of Cell Biology, Faculty of Biology, University of Bielefeld, Germany

Chronic rhinosinusitis (CRS) is marked by an inflamed mucosa of sinuses and is accompanied by a significantly reduced quality of live. Since no guidelines for the treatment of CRS are available, long lasting clinical histories with health care costs adding up to dozens of billion $ annually are caused by CRS. The progression of CRS is often induced by bacterial infections and/or a shift in microbiome as well as biofilm formation. The exact microbiome alterations are still unclear and the impenetrable biofilm renders the treatment with common antibiotics ineffective. This study focuses on characterizing the microbiome changes in CRS and investigating the inhibition of biofilm growth by 1,8-Cineol, a small, non-polar and hence biofilm penetrating molecule with known antimicrobial potential. We performed MALDI-TOF MS based characterization of the microbiomes of healthy individuals and CRS patients (n=50). The microbiome in our test group was shifted to pathogens (S. aureus, E. coli and M. catarrhalis). In contrast to published studies, solely based on cell culture techniques, we could not verify the abundance of P. aeruginosa in CRS. The inhibition of bacterial proliferation and biofilm growth by 1,8-Cineol was measured for these three pathogens. Interestingly, S. aureus, the most prominent germ in CRS, showed a biofilm inhibition not simply correlated to its inhibition of proliferation. RT-qPCR confirmed that this was due to the downregulations of major key players in biofilm generation (agrA, SarA and B) by 1,8-Cineol. Furthermore we verified this high biofilm inhibition potential in a model host system consisting out of S. aureus biofilm grown on mature respiratory epithelium. A second host model, comprising organotypic slices, was utilized to investigate the reaction of the innate immune system present in the nasal mucosa upon biofilm formation and treatment with 1,8-Cineol.
Interestingly S. epidermidis, the cause of very common catheter infections, possesses a biofilm generation pathway very similar to S. aureus and might be treatable in a similar fashion. The two presented in vitro model systems might be transferred to combinations of every biofilm forming bacterial with most kind of epithelium and mucosa.

Keywords: Biofilm, Chronic rhinosinusitis, S. aureus, host model system, 1,8-cineol

Received: 17 Apr 2019; Accepted: 24 Sep 2019.

Copyright: © 2019 Schürmann, Oppel, Gottschalk, Büker, Jantos, Prof. Dr. Knabbe, Hütten, Kaltschmidt, Kaltschmidt and Sudhoff. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mx. Holger Sudhoff, Bielefeld Clinic, Bielefeld, Germany, holger.sudhoff@rub.de